Prograf outperforms other anti-rejection drugs in study

12/20/2007 | Yahoo!

Researchers found small doses of Astellas Pharma's Prograf more effective than other drugs in preventing the immune system from rejecting transplanted kidneys. Patients who got low-dose Prograf recorded a short-term rejection rate of 12%, while recipients of Wyeth's low-dose Rapamune showed a rejection rate of 37%.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care